Hanwen Zhu, PhD, left, and Ji Sun, PhD, center, of the Dept. of Structural Biology, and Martin Turk, PhD, right, of the Cryo-Electron Microscopy Center discuss the structure of the active form of ...
The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.
Activating mutations on the EGFR protein, including exon 20 insertion mutations, have a role in NSCLC, but the associated structural changes resulting from the V769insASV and D770insNPG EGFR exon 20 ...
Scientists at St. Jude Children's Research Hospital revealed the complex structure of two Parkinson's disease-related proteins, both of which are implicated in late-onset cases. Leucine-rich repeat ...
More than 70 FDA-approved cancer drugs are kinase inhibitors, which work by blocking kinases—enzymes that add phosphate groups to molecules in the cell—and preventing the chemical activity necessary ...
The results of a study by New York University researchers explain why cancers can stop responding to kinase inhibitor drugs and may even come back stronger. By harnessing a range of analytical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results